---
title: "Genfit Reports Favorable Phase 1 Results for ACLF Drug Candidate G1090N"
description: "Genfit SA has reported positive Phase 1 results for its drug candidate G1090N, aimed at treating Acute-On-Chronic Liver Failure (ACLF). The trial, involving 76 healthy volunteers, demonstrated a favor"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271681233.md"
published_at: "2026-01-06T17:12:23.000Z"
---

# Genfit Reports Favorable Phase 1 Results for ACLF Drug Candidate G1090N

> Genfit SA has reported positive Phase 1 results for its drug candidate G1090N, aimed at treating Acute-On-Chronic Liver Failure (ACLF). The trial, involving 76 healthy volunteers, demonstrated a favorable safety and tolerability profile, along with significant anti-inflammatory activity. These results pave the way for G1090N to progress to Phase 2 studies. The findings have been presented, and the original content was published via GlobeNewswire.

Genfit SA has announced favorable Phase 1 results for its lead investigational drug candidate G1090N, intended for the treatment of Acute-On-Chronic Liver Failure (ACLF). The open-label Phase 1 trial assessed safety, tolerability, and pharmacokinetics in healthy volunteers through single and multiple ascending dose phases, enrolling a total of 76 participants. G1090N demonstrated a favorable safety and tolerability profile. Additionally, ex vivo studies showed that G1090N exhibited strong anti-inflammatory activity, with up to 76% inhibition of pro-inflammatory cytokine production in peripheral blood mononuclear cell assays. These findings support the advancement of G1090N into Phase 2 proof-of-concept studies. Results from the Phase 1 study have already been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001157948-en) on January 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GNFT.US - Genfit](https://longbridge.com/en/quote/GNFT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Genfit SA 在最新的公司報告中突出了其研發管線的進展以及商業上的成功 | Genfit SA 更新了其商業、臨牀和研究活動，報告了 Iqirvo® 在原發性膽汁性膽管炎方面的強勁銷售。該公司正在推進其研究候選藥物 G1090N 用於急性加重慢性肝衰竭的二期研究，並預計在 2026 年進行其腫瘤學項目 GNS561 | [Link](https://longbridge.com/en/news/275149217.md) |
| 再生元製藥稱其用於 FOP 的藥物候選者 Garetosmab 的生物製劑許可申請已獲得美國 FDA 的優先審查 | 再生元製藥表示，其 FOP 藥物候選者 Garetosmab 的生物製劑許可申請（BLA）獲得美國 FDA 優先審查 | [Link](https://longbridge.com/en/news/276347663.md) |
| 美國最危險的工作揭曉 | 在 2024 年，美國記錄了 5,070 起致命工作傷害，比 2023 年減少了 4%。卡車司機和建築工人受到的影響尤為明顯，卡車司機的死亡人數達到了 798 人。道路事故減少了 8.5%，而行人事故則上升了 19%。謀殺和自殺導致 733 | [Link](https://longbridge.com/en/news/276462715.md) |
| IDT 澳大利亞公司報告稱，通過新的領導團隊和重組戰略，其運營得到了改善 | IDT 澳大利亞在新的領導團隊和重新調整戰略下報告了運營改善，截止 12 月 31 日的六個月內，普通收入增長 20.3%，達到 840 萬美元。EBITDA 改善為虧損 43.6 萬美元，正常化的中期 EBITDA 為負 25.6 萬美元 | [Link](https://longbridge.com/en/news/276194130.md) |
| FDA 負責人警告美國在早期藥物開發上正在被中國趕超，呼籲加快試驗審批速度 | FDA 專員 Marty Makary 警告稱，美國在早期藥物開發方面正失去對中國的競爭優勢。他指出了三個主要瓶頸：醫院合同、倫理審查以及他所描述的低效的臨牀試驗新藥申請流程。Makary 強調需要進行改革，以簡化試驗審批，並建議與醫療系統 | [Link](https://longbridge.com/en/news/276268124.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.